REMARKS

13000

Claims 1-31 are presented in this application. In this amendment, claims 30 and 31 have been cancelled, and claims 5-8, 10-11, 13-15, 18, 19, 21, 23-24, 26, 28, and 29 have been amended to remove multiple dependencies for the purpose of reducing fees.

Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted in accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

Scott Young

Attorney for Applicant Registration No. 45,582

Date: <u></u> Dec 2005 GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-8160 Facsimile: 919-483-7988